
Jason E Stout

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5601506/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. Lancet Infectious Diseases, The, 2022, 22, 85-96.	9.1	23
2	Understanding and Communicating Risk: Assessing Both Relative and Absolute Risk Is Absolutely Necessary. JID Innovations, 2022, 2, 100097.	2.4	1
3	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infectious Diseases, The, 2022, 22, e178-e190.	9.1	51
4	Discordant results of tests for tuberculosis reconsidered – Authors' reply. Lancet Infectious Diseases, The, 2022, 22, 164-165.	9.1	0
5	Variability of interferon-Î ³ release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clinical Microbiology and Infection, 2022, , .	6.0	1
6	COVID-19 Trials: Who Participates and Who Benefits?. Southern Medical Journal, 2022, 115, 256-261.	0.7	2
7	To Boost or Not to Boost Residents and Fellows—That Is the Question. Journal of Graduate Medical Education, 2022, , .	1.3	0
8	Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth—United States, 2012–2017. Clinical Infectious Diseases, 2021, 73, e3468-e3475.	5.8	9
9	Tap Water Avoidance Decreases Rates of Hospital-onset Pulmonary Nontuberculous Mycobacteria. Clinical Infectious Diseases, 2021, 73, 524-527.	5.8	15
10	Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clinical Infectious Diseases, 2021, 72, 1127-1137.	5.8	23
11	Invasive <i>Mycobacterium abscessus</i> Complex Infection After Cardiac Surgery: Epidemiology, Management, and Clinical Outcomes. Clinical Infectious Diseases, 2021, 72, 1232-1240.	5.8	15
12	Social Disadvantage, Politics, and Severe Acute Respiratory Syndrome Coronavirus 2 Trends: A County-level Analysis of United States Data. Clinical Infectious Diseases, 2021, 72, e604-e607.	5.8	11
13	Reduction in Expected Survival Associated With Nontuberculous Mycobacterial Pulmonary Disease. Clinical Infectious Diseases, 2021, 72, e552-e557.	5.8	20
14	Optimising pyrazinamide for the treatment of tuberculosis. European Respiratory Journal, 2021, 58, 2002013.	6.7	15
15	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	12.8	194
16	Environmental risk factors associated with pulmonary isolation of nontuberculous mycobacteria, a population-based study in the southeastern United States. Science of the Total Environment, 2021, 763, 144552.	8.0	10
17	A Cluster of Nontuberculous Mycobacterial Tenosynovitis Following Hurricane Relief Efforts. Clinical Infectious Diseases, 2021, 72, e931-e937.	5.8	7
18	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 598-605.	5.6	7

#	Article	IF	CITATIONS
19	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, 905-913.	5.8	357
20	Universal masking is an effective strategy to flatten the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) healthcare worker epidemiologic curve. Infection Control and Hospital Epidemiology, 2020, 41, 1466-1467.	1.8	59
21	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. European Respiratory Journal, 2020, 56, 2000535.	6.7	336
22	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, e1-e36.	5.8	367
23	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 305-306.	5.6	0
24	Geographic analysis of latent tuberculosis screening: A health system approach. PLoS ONE, 2020, 15, e0242055.	2.5	1
25	877. Use of Statistical Process Control Charts for Early Detection of Healthcare Facility-Associated Nontuberculous Mycobacterial Outbreaks. Open Forum Infectious Diseases, 2020, 7, S475-S476.	0.9	0
26	Molecular Diagnostics for <i>Mycobacterium tuberculosis</i> Infection. Annual Review of Medicine, 2019, 70, 77-90.	12.2	23
27	Papulonecrotic tuberculid and Poncet disease: A case of multisystem delayed-type hypersensitivity in a patient with Mycobacterium tuberculosis infection. JAAD Case Reports, 2019, 5, 794-797.	0.8	5
28	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. New England Journal of Medicine, 2019, 381, e23.	27.0	9
29	1386. Reduction in Expected Survival Associated with Nontuberculous Mycobacterial Pulmonary Infection. Open Forum Infectious Diseases, 2019, 6, S503-S504.	0.9	0
30	Application of diagnostic criteria for non-tuberculous mycobacterial disease to a case series of mycobacterial-positive isolates. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 17, 100133.	1.3	4
31	<i>Nocardia</i> infections in the transplanted host. Transplant Infectious Disease, 2018, 20, e12902.	1.7	45
32	Annotated Genome Sequences of 16 Lineage 4 Mycobacterium tuberculosis Strains from Guatemala. Genome Announcements, 2018, 6, .	0.8	2
33	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal, 2018, 51, 1800170.	6.7	159
34	927. Tap Water Avoidance Decreases Rates of Nontuberculous Mycobacteria in Intensive Care Units. Open Forum Infectious Diseases, 2018, 5, S29-S30.	0.9	4
35	Impact of radiology reports on timely tuberculosis diagnosis. Postgraduate Medical Journal, 2018, 94, 495-498.	1.8	0
36	Evaluating latent tuberculosis infection diagnostics using latent class analysis. Thorax, 2018, 73, 1062-1070.	5.6	36

#	Article	IF	CITATIONS
37	Corticosteroids for tuberculous pericarditis: can we learn from variability?. International Journal of Tuberculosis and Lung Disease, 2018, 22, 475-475.	1.2	0
38	Health Care Utilization Behaviors Predict Disengagement From HIV Care: A Latent Class Analysis. Open Forum Infectious Diseases, 2018, 5, ofy088.	0.9	8
39	Infection-Induced Vascular Permeability Aids Mycobacterial Growth. Journal of Infectious Diseases, 2017, 215, jiw355.	4.0	46
40	Two-Phase Hospital-Associated Outbreak of <i>Mycobacterium abscessus</i> : Investigation and Mitigation. Clinical Infectious Diseases, 2017, 64, ciw877.	5.8	95
41	Increasing <i>Nocardia</i> Incidence Associated with Bronchiectasis at a Tertiary Care Center. Annals of the American Thoracic Society, 2017, 14, 347-354.	3.2	35
42	A Breath of Fresh Air for Patients with Pulmonary Nontuberculous Mycobacterial Infection. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 716-717.	5.6	0
43	Suboptimal HIV Testing Among Patients Admitted With Pneumonia: A Missed Opportunity. AIDS Education and Prevention, 2017, 29, 377-388.	1.1	8
44	Healthcare Engagement among Persons with HIV: More Than Just Viral Load and Clinic Attendance. Open Forum Infectious Diseases, 2017, 4, S419-S419.	0.9	0
45	Invasive Mycobacterium abscessus Infection after Cardiac Surgery: Epidemiology and Clinical Outcomes. Open Forum Infectious Diseases, 2017, 4, S35-S36.	0.9	0
46	Nocardia infections in the transplanted host. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
47	Incidence and Long-Term Outcomes of Patients With Human Immunodeficiency Virus and Disseminated Mycobacterium avium Complex From 1992 to 2015. Open Forum Infectious Diseases, 2016, 3, .	0.9	2
48	Calculating the economic benefits of what didn't happen. International Journal of Tuberculosis and Lung Disease, 2016, 20, 854-854.	1.2	1
49	Association Between Staff Experience and Effective Tuberculosis Contact Tracing in North Carolina, 2008-2009. North Carolina Medical Journal, 2016, 77, 37-44.	0.2	1
50	Update on pulmonary disease due to non-tuberculous mycobacteria. International Journal of Infectious Diseases, 2016, 45, 123-134.	3.3	267
51	Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes Infection. Immunity, 2016, 45, 861-876.	14.3	176
52	A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Medicine, 2016, 14, 51.	5.5	25
53	Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. International Journal of Tuberculosis and Lung Disease, 2016, 20, 827-831.	1.2	1
54	Medium matters: modeling the impact of solid medium performance on tuberculosis trial sample size requirements. International Journal of Tuberculosis and Lung Disease, 2016, 20, 600-604.	1.2	0

#	Article	IF	CITATIONS
55	Epidemiology of nontuberculous mycobacteria isolations among central North Carolina residents, 2006–2010. Journal of Infection, 2016, 72, 678-686.	3.3	49
56	Getting to a Man's Heart through His Colon. Texas Heart Institute Journal, 2016, 43, 168-170.	0.3	3
57	Mental Health and Substance Use Among Patients in a North Carolina HIV Clinic. North Carolina Medical Journal, 2015, 76, 148-155.	0.2	24
58	Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 333-343.	5.6	102
59	Treating multidrug-resistant tuberculosis in community settings: a wise investment. International Journal of Tuberculosis and Lung Disease, 2015, 19, 127-127.	1.2	1
60	The complexities of Xpert [®] MTB/RIF interpretation. International Journal of Tuberculosis and Lung Disease, 2015, 19, 273-275.	1.2	9
61	Twenty-eight cases of Mycobacterium marinum infection: retrospective case series and literature review. Infection, 2015, 43, 655-662.	4.7	113
62	The cost of 'free' tuberculosis care. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1413-1413.	1.2	1
63	Whole genome sequencing identifies circulating Beijing-lineage Mycobacterium tuberculosis strains in Guatemala and an associated urban outbreak. Tuberculosis, 2015, 95, 810-816.	1.9	16
64	The Human Antibody Response to the Surface of Mycobacterium tuberculosis. PLoS ONE, 2014, 9, e98938.	2.5	35
65	Integrated Screening for Tuberculosis and HIV in Tuberculosis Contact Investigations: Lessons Learned in North Carolina. Public Health Reports, 2014, 129, 21-25.	2.5	4
66	Advances in the management of pulmonary disease due to <i>Mycobacterium abscessus</i> complex. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1141-1148.	1.2	92
67	Barriers to Using Text Message Appointment Reminders in an HIV Clinic. Telemedicine Journal and E-Health, 2014, 20, 86-89.	2.8	31
68	<i>In Vitro</i> Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates. Journal of Clinical Microbiology, 2014, 52, 1311-1311.	3.9	2
69	Clinical Utility of Indium 111–Labeled White Blood Cell Scintigraphy for Evaluation of Suspected Infection. Open Forum Infectious Diseases, 2014, 1, ofu089.	0.9	23
70	Hepatitis B core antibodyâ€positive donors in cardiac transplantation: a singleâ€center experience. Transplant Infectious Disease, 2014, 16, 859-863.	1.7	5
71	Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infectious Diseases, 2014, 14, 74.	2.9	45
72	A randomized controlled trial of standard versus intensified tuberculosis diagnostics on treatment decisions by physicians in Northern Tanzania. BMC Infectious Diseases, 2014, 14, 89.	2.9	4

#	Article	IF	CITATIONS
73	Understanding the costs of better tuberculosis diagnostics. International Journal of Tuberculosis and Lung Disease, 2014, 18, 508-508.	1.2	0
74	lsoniazid preventive therapy in medium-incidence settings: the price is right. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1388-1388.	1.2	1
75	<i>In Vitro</i> Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates. Journal of Clinical Microbiology, 2013, 51, 3389-3394.	3.9	140
76	Public health costs for tuberculosis suspects in Wake County, North Carolina, United States. International Journal of Tuberculosis and Lung Disease, 2013, 17, 759-763.	1.2	5
77	The Footprint of Old Syphilis. Sexually Transmitted Diseases, 2013, 40, 839-841.	1.7	3
78	Nontuberculous Mycobacterial Infection after Fractionated CO ₂ Laser Resurfacing. Emerging Infectious Diseases, 2013, 19, 365-70.	4.3	26
79	The race to eliminate tuberculosis. North Carolina Medical Journal, 2013, 74, 415-9.	0.2	0
80	Treatment of <i>Mycobacterium abscessus</i> . American Journal of Respiratory and Critical Care Medicine, 2012, 186, 822-823.	5.6	32
81	Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium. Journal of Infectious Diseases, 2012, 206, 1030-1040.	4.0	98
82	Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health, 2012, 12, 468.	2.9	43
83	Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis. PLoS ONE, 2012, 7, e30194.	2.5	19
84	Geographic Information System-based Screening for TB, HIV, and Syphilis (GIS-THIS): A Cross-Sectional Study. PLoS ONE, 2012, 7, e46029.	2.5	40
85	Text Messaging for Enhancement of Testing and Treatment for Tuberculosis, Human Immunodeficiency Virus, and Syphilis: A Survey of Attitudes Toward Cellular Phones and Healthcare. Telemedicine Journal and E-Health, 2011, 17, 189-195.	2.8	55
86	Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection. PLoS ONE, 2011, 6, e22276.	2.5	20
87	Did the â€~Great Recession' produce a depression in tuberculosis incidence? [Short communication]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 700-702.	1.2	10
88	Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis, 2011, 91, 250-256.	1.9	123
89	Feasibility and willingness-to-pay for integrated community-based tuberculosis testing. BMC Infectious Diseases, 2011, 11, 305.	2.9	9
90	Increased prevalence of advanced tuberculosis in rural low tuberculosis caseload counties in North Carolina. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1455-1461.	1.2	6

#	Article	IF	CITATIONS
91	Pedicure-Associated Rapidly Growing Mycobacterial Infection: An Endemic Disease. Clinical Infectious Diseases, 2011, 53, 787-792.	5.8	51
92	Pairing QuantiFERON Gold In-Tube with Opt-Out HIV Testing in a Tuberculosis Contact Investigation in the Southeastern United States. AIDS Patient Care and STDs, 2010, 24, 539-543.	2.5	11
93	Treating latent tuberculosis with rifampin: is it the cheaper option?. Thorax, 2010, 65, 572-573.	5.6	3
94	It Is Better to Light a Candle … Than to Repeat the Opinions of Experts. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 865-866.	5.6	5
95	Effect of Improving the Quality of Radiographic Interpretation on the Ability to Predict Pulmonary Tuberculosis Relapse. Academic Radiology, 2010, 17, 157-162.	2.5	11
96	Influence of M. tuberculosis Lineage Variability within a Clinical Trial for Pulmonary Tuberculosis. PLoS ONE, 2010, 5, e10753.	2.5	40
97	HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons. AIDS Patient Care and STDs, 2009, 23, 845-851.	2.5	11
98	Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1055-1060.	5.6	86
99	Therapeutic Drug Monitoring of Antimycobacterial Drugs in Patients with Both Tuberculosis and Advanced Human Immunodeficiency Virus Infection. Pharmacotherapy, 2009, 29, 503-510.	2.6	45
100	Alcohol use and clinical manifestations of tuberculosis. Journal of Infection, 2009, 58, 395-401.	3.3	27
101	Corrigendum to "Alcohol use and clinical manifestations of tuberculosis―[J Infect 57 (2008) 385–391]. Journal of Infection, 2009, 58, 394.	3.3	0
102	Nontuberculous mycobacterial olecranon bursitis: Case reports and literature review. Journal of Shoulder and Elbow Surgery, 2009, 18, e1-e5.	2.6	12
103	Mortality and time to extubation in severe hospital-acquired pneumonia. American Journal of Infection Control, 2009, 37, 143-149.	2.3	9
104	Alcohol use and clinical manifestations of tuberculosis. Journal of Infection, 2008, 57, 385-391.	3.3	17
105	Extrapulmonary tuberculosis, human immunodeficiency virus, and foreign birth in North Carolina, 1993 – 2006. BMC Public Health, 2008, 8, 107.	2.9	35
106	Cavitary Pulmonary Disease. Clinical Microbiology Reviews, 2008, 21, 305-333.	13.6	299
107	Association between 16S-23S Internal Transcribed Spacer Sequence Groups of <i>Mycobacterium avium</i> Complex and Pulmonary Disease. Journal of Clinical Microbiology, 2008, 46, 2790-2793.	3.9	20
108	Predicting Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1055-1057.	5.6	20

#	Article	IF	CITATIONS
109	Tuberculosis knowledge, attitudes, and beliefs among North Carolinians at increased risk of infection. North Carolina Medical Journal, 2008, 69, 14-20.	0.2	26
110	Extensively Drug-Resistant Tuberculosis: Are We Learning from History or Repeating It?. Clinical Infectious Diseases, 2007, 45, 338-342.	5.8	32
111	Pharmacokinetics of Rifampicin. Clinical Infectious Diseases, 2007, 44, 618-619.	5.8	8
112	Central Nervous System Infection and Cutaneous Lymphadenitis Due to Mycobacterium kansasii in an Immunocompetent Patient. Infection, 2007, 35, 291-294.	4.7	5
113	Evaluation and management of patients with pulmonary nontuberculous mycobacterial infections. Expert Review of Anti-Infective Therapy, 2006, 4, 981-993.	4.4	14
114	Inhaled Azithromycin Therapy. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 54-60.	1.2	35
115	Racial and Ethnic Disparities in Pediatric Tuberculosis in North Carolina. JAMA Pediatrics, 2006, 160, 631.	3.0	25
116	Risk Factors for Ineffective Therapy in Patients With Bloodstream Infection. Archives of Internal Medicine, 2005, 165, 308.	3.8	69
117	Current issues in global tuberculosis control. International Journal of Infectious Diseases, 2005, 9, 297-311.	3.3	39
118	Tuberculosis Transmission from a Patient with Skin Lesions and a Negative Sputum Smear. New England Journal of Medicine, 2004, 350, 2527-2528.	27.0	2
119	Risk Factors for Infective Endocarditis in Patients with Enterococcal Bacteremia: A Case-Control Study. Infection, 2004, 32, 72-77.	4.7	68
120	Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety, 2004, 3, 187-198.	2.4	6
121	Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety, 2004, 3, 187-198.	2.4	2
122	Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 824-827.	5.6	74
123	Reactivation of Retinal Toxoplasmosis Despite Evidence of Immune Response to Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2002, 35, e37-e39.	5.8	13
124	Epidemiology of Human Immunodeficiency Virus Testing Among Patients With Tuberculosis in North Carolina. Southern Medical Journal, 2002, 95, 231-238.	0.7	8
125	Epidemiology of human immunodeficiency virus testing among patients with tuberculosis in North Carolina. Southern Medical Journal, 2002, 95, 231-8.	0.7	7
126	Hospital Management of Tuberculosis in a Region With a Low Incidence of Tuberculosis and a High Prevalence of Nontuberculous Mycobacteria. Infection Control and Hospital Epidemiology, 2001, 22, 715-717.	1.8	1